Keros Therapeutics is a biotechnology company focused on developing innovative therapies for hematological and musculoskeletal disorders with high unmet medical needs. Their research centers on the transforming growth factor-beta (TGF-ß) family of proteins, aiming to shift treatment paradigms for a wide range of patients. The company's mission is to discover and develop novel treatments that can significantly impact patient care globally.
Keros Therapeutics has made strides in advancing its pipeline, with notable progress in its elritercept (KER-) program. The company has presented clinical data at major medical conferences, demonstrating its commitment to scientific advancement and transparency. Keros continues to evolve its leadership structure to support its growth and research objectives, positioning itself as a key player in the biotechnology sector targeting TGF-ß-related disorders.
